Drug Trial Radar · NCT01792713
Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: May 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Feb 2013
Primary completion
Sep 2013
Study completion Feb 2014
Sponsor
- Lead sponsor
- Spirig Pharma Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 15, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigation aimed to explore the efficacy of a topical Sertaconazole cream 2% in patients with skin alterations associated with atopic dermatitis
Conditions
- Skin Alterations Associated With Atopic Dermatitis
Interventions
Sertaconazole 2% creamDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Patient Global Assessment (PGA)Time frame: day 1, day 28
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Universitätsmedizin Charité Berlin, Abteilung für Dermatologie und Allergologie
Berlin, Germany
Universitätsklinikum Münster, Klinik für Hautkrankheiten
Münster, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.